Anthropic's upcoming IPO has sparked investor interest in gaining exposure to the AI company before and after its public debut. The Tema Photonics & Optical ETF (LAZR) recently increased its allocation to Anthropic to 10.5%, making it a significant holding among ETFs. This move provides ordinary investors a way to invest in Anthropic ahead of its IPO, reflecting growing enthusiasm in the AI sector. The IPO filing has revived excitement around AI investments, suggesting more opportunities may arise post-IPO.
Anthropic's IPO and related AI investment interest provide context for this snapshot of the Technology sector on Pluang as of Oct 28, 2026 23:02 WIB: Among 150 priced US tech stocks, 64 rose and 85 fell. FIRY led gains with a 5.12% increase and 100% buy order activity, contrasting with CRSR's 5.16% decline and LRCX's 5.06% rise despite 69% sell order activity. Typical hold times ranged from 14 days for FIRY to 60 days for LRCX.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
